US Patent

US12168666 — Morphic forms of trilaciclib and methods of manufacture thereof

Composition of Matter · Assigned to G1 Therapeutics Inc · Expires 2040-11-13 · 14y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects an advantageous isolated morphic form of trilaciclib dihydrochloride, specifically its di-hydrochloride salt or dihydrochloride, dihydrate.

USPTO Abstract

An advantageous isolated morphic form of trilaciclib which is 2â²-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7â²,8â²-dihydro-6â²H-spiro[cyclohexane-1,9â²-pyrazino[1â²,2â²:1,5]pyrrolo[2,3-d]pyrimidin]-6â²-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: US12168666
Jurisdiction: US
Classification: Composition of Matter
Expires: 2040-11-13
Drug substance claim: Yes
Drug product claim: Yes
Assignee: G1 Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.